-
AI detects tumor disease – via voice recording
A short voice recording along with facial images – both analyzed with an AI algorithm – can make it possible to detect the rare tumour disease acromegaly and in...
-
From pharmacist to life science podcaster – Magnus Lejelöv uses his voice as a tool
Magnus Lejelöv has more than 20 years of experience in the pharmaceutical industry and has conducted nearly two hundred interviews with healthcare professionals...
-
The future of healthcare in focus: ”Together, things happen”
In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...
-
CROs in drug development: "We use our expertise to speed up the process
Consultancy firms have become an increasingly important part of drug development. “It’s a trend and a business model that works, and we see no indication that i...
-
Anna Törner: The minute between life and death
“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...
-
New diagnostic rules raise concerns
In a panel discussion, several voices from academia and the industry expressed concerns about the transition to the new regulatory framework for in-vitro diagno...
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
Science Sweden has spoken to Swedish researchers in Alzheimer’s who voice cautious hope but also see further challenges.
-
ALS – When the body has given up, but the brain persists
The nerve disease ALS gradually deprives the patient of control over the muscles and, eventually, also of speech. The eyes continue to function, though, and wit...
-
Bought a tablet factory – and built his own empire
In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...
-
Brexit creeping closer – or?
In this column, lawyer Pernilla Norman, tries to sort out the different Brexit options.
-
We are poor lobbyists
I doubt there has ever been a really well thought out Scandinavian campaign with intentions to really change attitudes among both the public and politicians.
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING